Fred runs the investing group Quantitative Risk & Value where he shares a portfolio invested in quality dividend stocks, and companies at the forefront of tech innovation. Fred also supplies market risk indicators, a real estate strategy, a bond strategy, and an income strategy in closed-end funds. Learn moreFred Piard, PhD. is a quantitative analyst and IT professional with over 30 years of experience working in technology. He is the author of three books and has been investing in data-driven systematic st ...

Power Solutions (NASDAQ: PSIX ) is an exciting rising star this year. Its stock price has skyrocketed. In this article, I will examine its growth trend and valuation status after the year-to-date price surge. I will also check its liquidity profile, which is importantI worked for over 10 years at large investment banks and insurance groups, before I chose to be an independent investment analyst. Quantitative analysis is my strength. I filter stocks using a data-driven approach, incorporating both technical ...

great piece by my quantitative Katie Haun: https://t.co/hmma2QieIU ...

Core Insights - Novo Nordisk was previously a leading player in the weight loss and diabetes drug markets but has experienced a significant decline in stock price from a peak of $148 in 2024 to its current level [1] Company Analysis - The decline in Novo Nordisk's stock price indicates potential challenges in maintaining its market dominance in the weight loss and diabetes sectors [1] Market Context - The performance of Novo Nordisk reflects broader trends in the pharmaceutical industry, particularly in the competitive landscape of diabetes and weight loss treatments [1]